{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:05:42Z","timestamp":1773284742203,"version":"3.50.1"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.ijantimicag.2007.03.009","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T01:36:27Z","timestamp":1180056987000},"page":"108-117","source":"Crossref","is-referenced-by-count":89,"title":["Recent advances in antifungal chemotherapy"],"prefix":"10.1016","volume":"30","author":[{"given":"George","family":"Petrikkos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Skiada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2007.03.009_bib1","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0161-5890(02)00022-6","article-title":"Invasive fungal infections: evolving challenges for diagnosis and therapeutics","volume":"38","author":"Ellis","year":"2002","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1086\/520192","article-title":"Nosocomial bloodstream infections in United States hospitals: a three-year analysis","volume":"29","author":"Edmond","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib3","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1086\/376634","article-title":"Amphotericin B: time for a new \u2018gold standard\u2019","volume":"37","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1023\/A:1010954803886","article-title":"In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature","volume":"150","author":"Espinel-Ingroff","year":"2001","journal-title":"Mycopathologia"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib7","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/AAC.47.9.2788-2795.2003","article-title":"Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults","volume":"47","author":"Courtney","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1128\/AAC.46.3.739-745.2002","article-title":"Single- and multiple-dose pharmacokinetics of caspofungin in healthy men","volume":"46","author":"Stone","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib9","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1177\/0091270005279580","article-title":"Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction","volume":"45","author":"Herbert","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib10","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1177\/0091270004265644","article-title":"Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal","volume":"44","author":"Dowell","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1345\/aph.1C261","article-title":"Voriconazole: a new triazole antifungal agent","volume":"37","author":"Pearson","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib12","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1086\/428734","article-title":"Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases","volume":"40","author":"Mouas","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib13","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/j.1651-2227.2003.tb00636.x","article-title":"Bone and joint infection after traumatic implantation of Scedosporium prolificans treated with voriconazole and surgery","volume":"92","author":"Studahl","year":"2003","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ajo.2004.08.077","article-title":"Management of endogenous fungal endophthalmitis with voriconazole and caspofungin","volume":"139","author":"Breit","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib15","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1086\/314042","article-title":"Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis","volume":"31","author":"Nesky","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib16","first-page":"1052","article-title":"Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia","volume":"98","author":"Schwarz","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib17","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(05)67490-9","article-title":"Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomized non-inferiority trial","volume":"366","author":"Kullberg","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib18","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s10096-003-1014-3","article-title":"Voriconazole salvage treatment of invasive candidiasis","volume":"22","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib19","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1086\/322653","article-title":"A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients","volume":"33","author":"Ally","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib20","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/374557","article-title":"Voriconazole treatment for less common, emerging, or refractory fungal infections","volume":"36","author":"Perfect","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib21","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib22","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","article-title":"Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis","volume":"34","author":"Denning","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib24","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1086\/421950","article-title":"Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases","volume":"39","author":"Steinbach","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib25","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1517\/13543784.11.3.409","article-title":"Review of the safety and efficacy of voriconazole","volume":"11","author":"Hoffman","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1086\/423274","article-title":"Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole","volume":"39","author":"Imhof","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib27","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1128\/AAC.41.10.2310","article-title":"Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp.","volume":"41","author":"Law","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib28","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1128\/AAC.41.1.180","article-title":"In vitro studies of activities of the antifungal triazoles SCH 56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts","volume":"41","author":"Galgiani","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib29","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1128\/AAC.41.5.1124","article-title":"In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp.","volume":"41","author":"Oakley","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1023\/A:1006970503053","article-title":"In vitro activity of a new triazole antifungal agent, SCH 56592, against clinical isolates of filamentous fungi","volume":"141","author":"Marco","year":"1998","journal-title":"Mycopathologia"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/13693780500088416","article-title":"In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi","volume":"43","author":"Gonzalez","year":"2005","journal-title":"Med Mycol"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib32","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1128\/AAC.48.3.804-808.2004","article-title":"Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men","volume":"48","author":"Courtney","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib33","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib34","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib35","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1086\/501457","article-title":"A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV\/AIDS","volume":"42","author":"Vazquez","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib36","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1128\/AAC.50.2.658-666.2006","article-title":"Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection","volume":"50","author":"Ullmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib37","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib38","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.50.1.126-133.2006","article-title":"Posaconazole as salvage therapy for zygomycosis","volume":"50","author":"Greenberg","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib39","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","article-title":"Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases","volume":"42","author":"Van Burik","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib40","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1086\/503425","article-title":"Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions","volume":"42","author":"Raad","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib41","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/jac\/dki288","article-title":"Activity of posaconazole in the treatment of central nervous system fungal infections","volume":"56","author":"Pitisuttithum","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib42","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1086\/430303","article-title":"Refractory coccidioidomycosis treated with posaconazole","volume":"40","author":"Anstead","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib43","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1086\/504328","article-title":"Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections","volume":"42","author":"Raad","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib44","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ejps.2004.01.005","article-title":"Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study","volume":"21","author":"Wexler","year":"2004","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib45","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1128\/AAC.44.10.2883-2886.2000","article-title":"In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans","volume":"44","author":"Yamazumi","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib46","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1128\/AAC.46.6.1723-1727.2002","article-title":"In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.","volume":"46","author":"Pfaller","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib47","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1128\/AAC.49.12.5136-5138.2005","article-title":"In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi","volume":"49","author":"Cuenca-Estrella","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib48","series-title":"41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 16\u201319 December 2001","article-title":"Randomized, double-blind study of the safety and antifungal activity of ravuconazole relative to fluconazole in esophageal candidiasis","author":"Beale","year":"2001"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib49","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1002\/hlca.19740570818","article-title":"Metabolics of microorganisms. Echinocandin B, a novel polypeptide-antibiotic from Aspergillus nidulans var. echinulatus: isolation and structural components","volume":"57","author":"Nyfeler","year":"1974","journal-title":"Helv Chim Acta"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib50","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1128\/AAC.44.2.368-377.2000","article-title":"Discovery of novel antifungal (1,3)-\u03b2-d-glucan synthase inhibitors","volume":"44","author":"Onishi","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib51","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1128\/AAC.41.7.1612","article-title":"In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species","volume":"41","author":"Vazquez","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib52","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s100960050283","article-title":"In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species","volume":"18","author":"Barchiesi","year":"1999","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib53","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1128\/AAC.49.9.3616-3623.2005","article-title":"Caspofungin susceptibility testing of isolates from patients with esophageal or invasive candidiasis: relationship of MIC to treatment outcome","volume":"49","author":"Kartsonis","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib54","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1128\/AAC.49.8.3264-3273.2005","article-title":"Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates","volume":"49","author":"Park","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib55","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s10096-003-0973-8","article-title":"Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis","volume":"22","author":"Colombo","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib56","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1128\/AAC.49.2.767-769.2005","article-title":"Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis","volume":"49","author":"Moudgal","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib57","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1128\/AAC.48.4.1382-1383.2004","article-title":"Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis","volume":"48","author":"Hernandez","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib58","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1086\/500939","article-title":"Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient","volume":"42","author":"Krogh-Madsen","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib59","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0732-8893(97)00246-0","article-title":"In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus and other filamentous fungi","volume":"30","author":"Pfaller","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib60","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1128\/AAC.41.11.2333","article-title":"Evaluation of echinocandin antifungal MK-0991 (l-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis and cryptococcosis","volume":"41","author":"Abruzzo","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib61","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0002-9343(02)01191-9","article-title":"A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis","volume":"113","author":"Villanueva","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib62","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/AAC.46.2.451-457.2002","article-title":"Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis","volume":"46","author":"Arathoon","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib63","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1086\/323401","article-title":"A randomized double-blind study of caspofungin versus amphotericin B for the treatment of candidal esophagitis","volume":"33","author":"Villanueva","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib64","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib65","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patient refractory to or intolerant of conventional antifungal therapy","volume":"39","author":"Maertens","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib66","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jinf.2004.05.011","article-title":"Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study","volume":"50","author":"Kartsonis","year":"2005","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib67","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib68","unstructured":"Merck & Co. Cancidas prescribing information. Whitehouse Station, NJ: Merck; 2004."},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib69","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1128\/AAC.48.11.4306-4314.2004","article-title":"Potential for interactions between caspofungin and nelfinavir or rifampin","volume":"48","author":"Stone","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib70","unstructured":"Caspofungin (Cancidas) for aspergillosis. Med Lett Drugs Ther 2001; 43:58."},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib71","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1399-3062.2004.00065.x","article-title":"Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A","volume":"6","author":"Marr","year":"2004","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib72","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/00365540410020406","article-title":"A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan","volume":"36","author":"Kohno","year":"2004","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib73","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1365-2036.2005.02427.x","article-title":"A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis","volume":"21","author":"de Wet","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib74","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2036.2004.02083.x","article-title":"Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent","volume":"20","author":"Pettengell","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib75","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1086\/423377","article-title":"A randomized, double-blind, parallel-group, dose\u2013response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients","volume":"39","author":"de Wet","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib76","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s10096-005-0024-8","article-title":"International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia","volume":"24","author":"Ostrosky-Zeichner","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib77","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib78","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1532\/IJH97.03163","article-title":"Successful micafungin (FK463) treatment of invasive pulmonary aspergillosis in a patient with acute lymphoblastic leukemia in a phase II study","volume":"79","author":"Ota","year":"2004","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib79","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00277-003-0736-8","article-title":"Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy","volume":"88","author":"Yokote","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib80","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00043426-200303000-00014","article-title":"Successful treatment of invasive aspergillosis in two patients with acute myeloid leukaemia","volume":"25","author":"Singer","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib81","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1177\/0091270005278601","article-title":"Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers","volume":"45","author":"Hebert","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib82","series-title":"Micafungin (Mycamine) for fungal infections","author":"Astellas","year":"2005"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib83","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/jac\/dkg018","article-title":"Antifungal activity of the echinocandin anidulafungin (VER002,LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method","volume":"51","author":"Ar\u00e9valo","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib84","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1128\/AAC.41.4.863","article-title":"In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species","volume":"41","author":"Zhanel","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib85","unstructured":"Efficacy of anidulafungin (ANID) in patients (pts) with azole-refractory mucosal candidiasis (ARMC). In: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 30 October\u20132 November 2004; Washington, DC. Washington, DC: ASM Press; 2004 [abstract M-1038]."},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib86","unstructured":"Phase II, randomized, open-label study of two intravenous dosing regimens of V-echinocandin in the treatment of esophageal candidiasis. In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 17\u201320 September 2000; Toronto, Ontario. Washington, DC: ASM Press; 2000. [abstract 1106]."},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib87","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/423378","article-title":"A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis","volume":"39","author":"Krause","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib88","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1128\/AAC.48.6.2021-2024.2004","article-title":"Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia","volume":"48","author":"Krause","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib89","unstructured":"Anidulafungin vs. fluconazole for treatment of candidemia and invasive candidiasis (C\/IC). In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 16-19 December 2005; Washington, DC. Washington, DC: ASM Press; 2005. [abstract M-718]."},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib90","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/ajhp\/62.8.834","article-title":"Compatibility of anidulafungin with other drugs during simulated Y-site administration","volume":"62","author":"Trissel","year":"2005","journal-title":"Am J Health Syst Pharm"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2007.03.009_bib91","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijantimicag.2006.03.016","article-title":"Antifungal combination treatment: a future perspective","volume":"27","author":"Fohrer","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2007.03.009_bib92","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/01.qco.0000235166.16421.e5","article-title":"The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine","volume":"19","author":"Chamilos","year":"2006","journal-title":"Curr Opin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857907001811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857907001811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,28]],"date-time":"2019-04-28T05:15:43Z","timestamp":1556428543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857907001811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0924857907001811"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2007.03.009","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}